mTOR medicines for healthier aging in older adults
Official title: Characterization of mTOR Inhibitor Pharmacokinetics and Pharmacodynamics in Older Adults .
Run by University of Texas Southwestern Medical Center · NCT06727305 · Data updated 2026-11-12
This trial will test two mTOR drugs, sirolimus and everolimus, in people 65 and older to measure drug levels and see if they improve biomarkers of aging.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 65 Years to 80 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | May 11, 2026 |
| Main results expected | September 1, 2027 |
| Study ends | November 13, 2027 |
| Registry record updated | June 25, 2026 |
| Trial ID | NCT06727305 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are community-dwelling adults aged 65 or older who can understand and follow procedures and do not have severe kidney or liver disease, uncontrolled hypertension, recent major cardiovascular or hemorrhagic/thrombotic events, dementia, dependence in basic ADLs, or medications that significantly interact with sirolimus/everolimus.
✕Probably not a fit
Patients with creatinine clearance <30 mL/min, chronic liver disease, uncontrolled systolic blood pressure >160 mm Hg, recent CNS hemorrhage or recent thrombotic events without anticoagulation, recent heart failure or myocardial infarction, dementia, dependence in Katz ADLs, or taking drugs that alter sirolimus levels are unlikely to be eligible and may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1/2 interventional trial will give older adults short courses of sirolimus or everolimus and collect serial blood samples to define pharmacokinetics and pharmacodynamics in this age group. Researchers will measure a senescence-associated secretory phenotype (SASP) index at baseline and 3 months to see whether those biomarkers shift with treatment. The study also collects exploratory laboratory measures (ESR, CRP, S6K activity, mitochondrial function, metabolomics) and functional tests (walking speed, chair stand, standing balance, grip strength). Results are intended to define safe dosing and biological signals to guide larger trials of mTOR inhibitors for aging-related outcomes.
Why it matters
Potential benefit: If successful, the trial could identify safe dosing and show whether mTOR inhibitors alter aging-related biomarkers, laying groundwork for larger studies aimed at slowing functional decline.
How similar studies have gone: Prior animal studies and small human trials have suggested mTOR inhibitors can modify aging pathways and improve immune or metabolic markers, but robust PK/PD and aging-biomarker data in older adults are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Community-dwelling adults 2. Patients should be 65 Years and older 3. Patients is able to understand and follow trial procedures Exclusion Criteria: 1. Creatinine clearance \<30 mL/min; 2. History of chronic liver disease; 3. Uncontrolled Hypertension (i.e., systolic blood pressure \>160 mm Hg); 4. Hemorrhagic central nervous system (CNS) event within 1 year from screening visit; 5. Thrombotic event (DVT,PE) within 1 year from screening visit if not on anticoagulation; 6. Planned major surgical procedures; 7. Cardiovascular diseases ( i.e., admission for heart failure or myocardial infarction within 12 months); 8. Taking medication that increase or decrease sirolimus blood concentrations; 9. Other investigational therapy received within 1 month prior to screening visit; 10. History of dementia; 11 Dependence in any Katz Basic Activities of Daily Living.
Where it's running
-
UT Southwestern Medical Center
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Irina Timofte, MD, MS — University of Texas Southwestern Medical Center
- Study coordinator: Irina Timofte, MD, MS
- Email: Irina.Timofte@utsouthwestern.edu
- Phone: 2163347534
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aquatic power training dosing strategies and creatine in older adults
This trial tests whether different aquatic power training dosing methods and creatine supplementation help improve function in community-dwelling adults aged 60 and older.
-
Intergenerational Interaction Program for Nursing Home Residents and Nursing Students
A 6-week program pairs nursing home residents with nursing students to see if weekly joint activities can increase joy and reduce loneliness for older adults and lessen ageism in students.
-
Supplemental Mobility for older adults in skilled nursing facilities
This pilot tests whether adding a mobility aide to support walking and transfers alongside regular rehab helps older adults in SNFs after hospitalization see more daily activity and safer mobility.
-
Smart Voice Platform to Support Quality of Life for Community-Living Older Adults
A smart voice platform is tested to see if it improves quality of life and healthy aging for older adults living in the community.
-
Digital STEADI: A home-based digital fall prevention program for older adults
A home-based digital program using AI-driven conversational agents tests if a guided fall-prevention exercise plan can reduce fall risk for older adults with mild cognitive impairment living independently.
-
Sex hormones, menopause, and exercise in aging women
This study tests how hormonal status and resistance training affect age-related muscle and nerve function in postmenopausal women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.